Baximo 25 mg/100 mg Powder for concentrate for solution for infusion.
PDF Leaflet Revision Date: 05 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific leukemias and lymphomas.
Dosage (summary)
100 mg/mu00b2 on days 1 and 2 every 4 weeks for CLL; 90 mg/mu00b2 with rituximab for NHL.
Onset of Action / Duration
Onset: 30 mins, Duration: 4 weeks
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP1A2 inhibitors
- Myelosuppressive agents
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Pregnancy
- Lactation
Common side effects
- Infection
- Leukopenia
- Nausea
- Vomiting
- Fatigue
Counselling Points
- Monitor for signs of infection
- Use effective contraception
- Avoid driving if experiencing ataxia or somnolence
Serious warnings
- Myelosuppression
- Infection risk
- Hepatitis B reactivation
- Severe skin reactions
- Cardiac disorders
Important Disclaimer
The Baximo 25 mg/100 mg Powder for concentrate for solution for infusion. professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
